Exploring the active mechanism of berberine against HCC by systematic pharmacology and experimental validation

Berberine (BBR) is the main component of Coptidis rhizoma, the dried rhizome of Coptis chinensis and is a potential plant alkaloid used for the treatment of cancer due to its high antitumor activity. The present study examined the therapeutic potential and molecular mechanism of action of BBR against HCC, using systematic pharmacology combined with a molecular docking approach and experimental validation in vitro. Through systematic pharmacological analysis, it was found that BBR serves a significant role in inhibiting HCC by affecting multiple pathways, especially the PI3K/AKT signaling pathway. Furthermore, the docking approach indicated that the binding of BBR to AKT could lead to the suppression of AKT activity. The present study examined the inhibitory effect of BBR on the PI3K/AKT pathway in HCC and identified that BBR downregulated the expressions of phosphorylated AKT and PI3K in MHCC97-H and HepG2 cells, inhibiting their growth, cell migration and invasion in a dose-dependent manner. In addition, inhibition of the AKT pathway by BBR also contributed to cell apoptosis in MHCC97-H and HepG2 cells. Taken together, the results of the present study suggested that BBR may be a promising antitumor drug for HCC that acts by inhibiting the PI3K/AKT pathway.

[1]  M. Provinciali,et al.  Antitumor effect of novel berberine derivatives in breast cancer cells. , 2013, BioFactors.

[2]  Dong-fang Wu,et al.  Berberine hydrochloride impact on physiological processes and modulation of twist levels in nasopharyngeal carcinoma CNE-1 cells. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[3]  S. Tsao,et al.  Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: The cellular mechanism , 2010, Journal of cellular biochemistry.

[4]  R. Rahimi,et al.  Plant-derived natural agents as dietary supplements for the regulation of glycosylated hemoglobin: A review of clinical trials. , 2020, Clinical nutrition.

[5]  Ning Wang,et al.  Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine , 2016, International journal of molecular sciences.

[6]  Shey-Cherng Tzou,et al.  Discovery of Akt Kinase Inhibitors through Structure-Based Virtual Screening and Their Evaluation as Potential Anticancer Agents , 2015, International journal of molecular sciences.

[7]  Markus Peck-Radosavljevic,et al.  Review article: systemic treatment of hepatocellular carcinoma , 2018, Alimentary pharmacology & therapeutics.

[8]  A. Toker,et al.  AKT/PKB Signaling: Navigating the Network , 2017, Cell.

[9]  Xinchen Sun,et al.  Berberine inhibits the expression of hypoxia induction factor-1alpha and increases the radiosensitivity of prostate cancer , 2014, Diagnostic Pathology.

[10]  Yibin Feng,et al.  A Network-Based Pharmacology Study of the Herb-Induced Liver Injury Potential of Traditional Hepatoprotective Chinese Herbal Medicines , 2017, Molecules.

[11]  Na Li,et al.  Berberine exhibits antitumor effects in human ovarian cancer cells. , 2015, Anti-cancer agents in medicinal chemistry.

[12]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Aurélien Grosdidier,et al.  Docking, virtual high throughput screening and in silico fragment-based drug design , 2009, Journal of cellular and molecular medicine.

[14]  Wen-Hui Su,et al.  OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci , 2006, Nucleic Acids Res..

[15]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[16]  Wei Zhang,et al.  Coupling function of cyclin‐dependent kinase 2 and Septin2 in the promotion of hepatocellular carcinoma , 2018, Cancer science.

[17]  Yuxia Zhao,et al.  Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. , 2008, European journal of cancer.

[18]  P. Xiao,et al.  Network Pharmacology: A Rosetta Stone for Traditional Chinese Medicine , 2014, Drug development research.

[19]  Ning Wang,et al.  A Biomedical Investigation of the Hepatoprotective Effect of Radix salviae miltiorrhizae and Network Pharmacology-Based Prediction of the Active Compounds and Molecular Targets , 2017, International journal of molecular sciences.

[20]  Xin Wang,et al.  Berberine increases the expression of NHE3 and AQP4 in sennosideA-induced diarrhoea model. , 2012, Fitoterapia.

[21]  Jiansong Fang,et al.  An Insight Into the Molecular Mechanism of Berberine Towards Multiple Cancer Types Through Systems Pharmacology , 2019, Front. Pharmacol..

[22]  Osmar Norberto de Souza,et al.  A selective method for optimizing ensemble docking-based experiments on an InhA Fully-Flexible receptor model , 2018, BMC Bioinformatics.

[23]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[24]  Xingchun Wang,et al.  Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  H. Hosseinzadeh,et al.  Berberis Vulgaris and Berberine: An Update Review , 2016, Phytotherapy research : PTR.

[26]  Wei Zhou,et al.  TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.

[27]  A. Scovassi,et al.  Berberine: new perspectives for old remedies. , 2012, Biochemical pharmacology.

[28]  Hua Yu,et al.  A Systematic Prediction of Multiple Drug-Target Interactions from Chemical, Genomic, and Pharmacological Data , 2012, PloS one.

[29]  J. Engelman,et al.  The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[31]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[32]  Xiaocheng Li,et al.  Matrix Metalloproteinase 2 Knockdown Suppresses the Proliferation of HepG2 and Huh7 Cells and Enhances the Cisplatin Effect , 2019, Open medicine.

[33]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[34]  A. Lamarca,et al.  Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival , 2017, Expert review of gastroenterology & hepatology.

[35]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[36]  Kun Wang,et al.  Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells. , 2016, Biochemical and biophysical research communications.

[37]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[38]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[39]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..